Cannabidiol arrests onset of autoimmune diabetes in NOD mice

NEUROPHARMACOLOGY

卷:54

Article

Weiss, Lola¹  Zeira, Michael¹  Reich, Shoshana¹  Slavin, Shimon¹  Raz, Itamar²  Mechoulam, Raphael³  Gallily, Ruth⁴ 

[1] Hadassah Hebrew Univ Hosp, Dept Bone Marrow Transplantat & Canc Immunotherap, IL-91120 Jerusalem, Israel

[2] Hadassah Hebrew Univ Med Sch, Dept Internal Med, IL-91120 Jerusalem, Israel

[3] Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel

[4] Hebrew Univ Jerusalem, Sch Med, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel

关键词: cannabinoids;    cannabidiol;    diabetes;    NOD mice;    cytokines;   

DOI  :  10.1016/j.neuropharm.2007.06.029

来源: Elsevier

【 摘 要 】

We have previously reported that cannabidiol (CBD) lowers the incidence of diabetes in young non-obese diabetes-prone (NOD) female mice. In the present study we show that administration of CBD to 11-14 week old female NOD mice, which are either in a latent diabetes stage or with initial symptoms of diabetes, ameliorates the manifestations of the disease. Diabetes was diagnosed in only 32% of the mice in the CBD-treated group, compared to 86% and 100% in the emulsifier-treated and untreated groups, respectively. In addition, the level of the proinflammatory cytokine IL-12 produced by splenocytes was significantly reduced, whereas the level of the anti-inflammatory IL-10 was significantly elevated following CBD-treatment. Histological examination of the pancreata of CBD-treated mice revealed more intact islets than in the controls. Our data strengthen our previous assumption that CBD, known to be safe in man, can possibly be used as a therapeutic agent for treatment of type 1 diabetes. (c) 2007 Elsevier Ltd. All rights reserved.

【 授权许可】

Free